ABCL Q1 2022 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$317M+56.2% YoY

Gross Profit

$272M85.9% margin

Operating Income

$225M71.1% margin

Net Income

$169M53.2% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

+127.2%

Cash Flow

Operating Cash Flow

$100M

Free Cash Flow

$86M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$385M

Stockholders' Equity

$1.2B

Cash & Equivalents

$546M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$317M	$203M	+56.2%
Gross Profit	$272M	$183M	+48.8%
Operating Income	$225M	$158M	+42.3%
Net Income	$169M	$117M	+43.8%

Revenue Segments

Royalty

$307M97%

Research Fees

$9M3%

License

$231,0000%